Viking Therapeutics reports results from Phase 2b clinical ... - Nasdaq

3 days ago · Viking Therapeutics (VKTX) announced that final results from the company’s Phase 2b clinical trial of VK2809, the company’s novel liver-selective thyroid hormone receptor beta …

CouponFollow Extension

15%
OFF

Viking Therapeutics Gains On Early Data For Oral Weight Loss …

6 days from now

7mo. S hares of Viking Therapeutics (NASDAQ: VKTX) gained ~15% premarket Tuesday after the company said its oral once-daily obesity therapy VK2735 caused up to ~5% of weight loss …

msn.com

8%
OFF

Viking Joins Obesity Drug Development Race With Early Study Data

6 days from now

Mar 28, 2023 · Dive Brief: An injection being developed by biotechnology company Viking Therapeutics for obesity helped adults enrolled in a small clinical trial lose up to 8% of their …

biopharmadive.com

$300
OFF

Viking To Charge Quickly Into Phase 3 With Obesity Med

6 days from now

Jul 25, 2024 · Viking's obesity med set to charge into phase 3, with $300M earmarked for clinical program. By Annalee Armstrong Jul 25, 2024 9:19am. Viking Therapeutics Earnings obesity …

fiercebiotech.com

70%
OFF

Viking Obesity Med Passes Phase 1 Test, Sending Shares Sky High

6 days from now

Mar 28, 2023 · Viking Therapeutics was a stock market winner Tuesday after encouraging phase 1 data posted earlier in the day sent shares up nearly 70%. The company reported Tuesday …

fiercebiotech.com

$6.86
OFF

Better Rising Biotech: Viking Therapeutics Vs. Summit Therapeutics

6 days from now

Sep 28, 2024 · Viking Therapeutics' market cap is $6.86 billion. Summit Therapeutics' is more than twice that at $17.39 billion. Summit is worth more partly because its leading candidate …

fool.com

04%
OFF

The Bull Case For Viking Therapeutics Just Got Even Stronger.

6 days from now

Jul 29, 2024 · Viking Therapeutics (VKTX 0.04%) just gave shareholders a few more reasons to be excited for the future. With its shares soaring by a stunning 34% on July 25 thanks to …

fool.com

FAQs about Viking Therapeutics reports results from Phase 2b clinical ... - Nasdaq Coupon?

Who is Viking Therapeutics?

About Viking Therapeutics, Inc. Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. ...

Does Viking Therapeutics have a steatohepatitis treatment program?

Viking Therapeutics has other programs as well. The company is working on an oral version of VK2735 that also produced promising phase 1 results. Elsewhere, the company's VK2809 is a potential therapy for metabolic dysfunction-associated steatohepatitis. ...

Will vk2735's results send Viking Therapeutics' shares through the roof?

Though it still has to undergo a phase 3 clinical trial, VK2735's results were impressive enough to send Viking Therapeutics' shares through the roof. Some analysts have also predicted potential mouthwatering sales for the medicine. ...

How much money does Viking spend on research & development?

To accomplish all of that in one quarter, Viking only spent $23.8 million on research and development (R&D). Given the number of clinical trials it's running, the gargantuan market for weight loss drugs that it's working to enter, and its cash and investments of $942 million, that's practically free. ...

Could Viking Therapeutics' oral obesity drug be better than wegovy & zepbound?

Michael M. Santiago via Getty Images New results from a small study of Viking Therapeutics’ oral obesity drug raised expectations among Wall Street analysts that the experimental tablet could prove superior among the growing ranks of would-be competitors to the popular weight loss treatments Wegovy and Zepbound. ...

Is Viking Therapeutics a safe harbor company?

This press release contains forward-looking statements regarding Viking Therapeutics, Inc., under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its clinical and preclinical development programs and cash resources. ...